Skip to main
LFCR

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical has demonstrated notable growth in its HA manufacturing segment, primarily driven by favorable order timing from its largest customer, indicating strong demand for its services. The company is positioned for significant operational momentum, with expectations of meaningful commercial revenue generation as early as 2027, paving the way for a potential breakout year in 2028. Additionally, Lifecore aims to increase its capacity utilization from 20% in 2025 to 60% by 2029, supporting a targeted revenue compound annual growth rate (CAGR) of 12%, which highlights the company's positive outlook in the medium to long term.

Bears say

Lifecore Biomedical has experienced a significant decline in share price, dropping over 50% in the past two months, primarily attributed to disappointing fiscal year 2026 guidance and conservative expectations for fiscal year 2027 top-line growth. The company reported a noticeable decline in CDMO revenue, driven by the absence of take-or-pay arrangements and decreased aseptic sales volumes, amid a challenging revenue landscape compounded by a $17 million to $18 million headwind from customer losses, inventory rebalancing, and delayed product launches. Additionally, uncertainties regarding the potential need for a capital raise further contribute to a cautious outlook on the company's financial stability and performance prospects.

LFCR has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Buy based on their latest research and market trends.

According to 1 analysts, LFCR has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.